Screener
Vera Therapeutics VERA Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $13,909 | $21,898 |
| Accrued expenses and other liabilities, current | 31,240 | 31,557 |
| Total current liabilities | 45,149 | 53,455 |
| Long-term debt | 75,029 | 74,838 |
| Other liabilities, noncurrent | 1,864 | 1,919 |
| Total liabilities | 122,042 | 130,212 |
| Stockholders’ equity | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,730,090 and 71,267,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 72 | 71 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's long-term debt?
- Vera Therapeutics (VERA) reported long-term debt of $75.03M in Q1 2026.
- How has Vera Therapeutics's long-term debt changed year-over-year?
- Vera Therapeutics's long-term debt increased by 47.4% year-over-year, from $50.91M to $75.03M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Vera Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude